Literature DB >> 20179147

Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.

Kahina Oussedik1, Jean-Christophe François, Ludovic Halby, Catherine Senamaud-Beaufort, Géraldine Toutirais, Sabrina Dallavalle, Yves Pommier, Claudio Pisano, Paola B Arimondo.   

Abstract

We and others have clearly demonstrated that a topoisomerase I (Top1) inhibitor, such as camptothecin (CPT), coupled to a triplex-forming oligonucleotide (TFO) through a suitable linker can be used to cause site-specific cleavage of the targeted DNA sequence in in vitro models. Here we evaluated whether these molecular tools induce sequence-specific DNA damage in a genome context. We targeted the insulin-like growth factor (IGF)-I axis and in particular promoter 1 of IGF-I and intron 2 of type 1 insulin-like growth factor receptor (IGF-IR) in cancer cells. The IGF axis molecules represent important targets for anticancer strategies, because of their central role in oncogenic maintenance and metastasis processes. We chemically attached 2 CPT derivatives to 2 TFOs. Both conjugates efficiently blocked gene expression in cells, reducing the quantity of mRNA transcribed by 70-80%, as measured by quantitative RT-PCR. We confirmed that the inhibitory mechanism of these TFO conjugates was mediated by Top1-induced cleavage through the use of RNA interference experiments and a camptothecin-resistant cell line. In addition, induction of phospho-H2AX foci supports the DNA-damaging activity of TFO-CPT conjugates at specific sites. The evaluated conjugates induce a specific DNA damage at the target gene mediated by Top1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179147      PMCID: PMC2887256          DOI: 10.1096/fj.09-132324

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  52 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

Review 2.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 3.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

4.  Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.

Authors:  S Dallavalle; A Ferrari; B Biasotti; L Merlini; S Penco; G Gallo; M Marzi; M O Tinti; R Martinelli; C Pisano; P Carminati; N Carenini; G Beretta; P Perego; M De Cesare; G Pratesi; F Zunino
Journal:  J Med Chem       Date:  2001-09-27       Impact factor: 7.446

Review 5.  Insulin-Like Growth Factor (IGF) family and prostate cancer.

Authors:  C Gennigens; C Menetrier-Caux; J P Droz
Journal:  Crit Rev Oncol Hematol       Date:  2006-01-18       Impact factor: 6.312

6.  Triplex formation by oligonucleotides containing 5-(1-propynyl)-2'-deoxyuridine: decreased magnesium dependence and improved intracellular gene targeting.

Authors:  L Lacroix; J Lacoste; J F Reddoch; J L Mergny; D D Levy; M M Seidman; M D Matteucci; P M Glazer
Journal:  Biochemistry       Date:  1999-02-09       Impact factor: 3.162

7.  Targeting MDR1 gene: synthesis and cellular study of modified daunomycin-triplex-forming oligonucleotide conjugates able to inhibit gene expression in resistant cell lines.

Authors:  Vérène Stierlé; Maria Duca; Ludovic Halby; Catherine Senamaud-Beaufort; Massimo L Capobianco; Alain Laigle; Béatrice Jollès; Paola B Arimondo
Journal:  Mol Pharmacol       Date:  2008-02-25       Impact factor: 4.436

Review 8.  Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer.

Authors:  John S P Yuen; Valentine M Macaulay
Journal:  Expert Opin Ther Targets       Date:  2008-05       Impact factor: 6.902

9.  DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.

Authors:  Giuseppina M Carbone; Eileen McGuffie; Sara Napoli; Courtney E Flanagan; Chiara Dembech; Umberto Negri; Federico Arcamone; Massimo L Capobianco; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2004-04-30       Impact factor: 16.971

Review 10.  The IGF-I axis in thyroid carcinoma.

Authors:  A Ciampolillo; C De Tullio; E Perlino; E Maiorano
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more
  7 in total

1.  Targeted gene correction using psoralen, chlorambucil and camptothecin conjugates of triplex forming peptide nucleic acid (PNA).

Authors:  Henrik Birkedal; Peter E Nielsen
Journal:  Artif DNA PNA XNA       Date:  2011-01

Review 2.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

3.  Regulation of transcription through light-activation and light-deactivation of triplex-forming oligonucleotides in mammalian cells.

Authors:  Jeane M Govan; Rajendra Uprety; James Hemphill; Mark O Lively; Alexander Deiters
Journal:  ACS Chem Biol       Date:  2012-05-11       Impact factor: 5.100

4.  Replication-fork stalling and processing at a single psoralen interstrand crosslink in Xenopus egg extracts.

Authors:  Cyrille Le Breton; Magali Hennion; Paola B Arimondo; Olivier Hyrien
Journal:  PLoS One       Date:  2011-04-15       Impact factor: 3.240

5.  Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.

Authors:  Tiphanie Durfort; Mercedes Tkach; Mariya I Meschaninova; Martín A Rivas; Patricia V Elizalde; Alya G Venyaminova; Roxana Schillaci; Jean-Christophe François
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

6.  Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.

Authors:  Fung-Ming Siu; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2013-09-09       Impact factor: 16.971

Review 7.  Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?

Authors:  Ben D Bax; Dmitry Sutormin; Neil Q McDonald; Glenn A Burley; Tatyana Shelkovnikova
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.